News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Solos Endoscopy, Inc. (SLSE.PK) Sales Increases by More Than 53% for the Month of November, 2012


12/14/2012 9:52:00 AM

BOSTON, Dec. 14, 2012 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company's sales for the month of November increased by more than 53%. Solos Endoscopy's sales increased from $27,818.96 for November 2011 to $42,631.56 for November 2012.

Solos management expected sales to be greater in the month of November due to the fact that several orders scheduled to be shipped to tri-state hospitals in October were pushed back to November due to Hurricane Sandy. Solos Endoscopy's amended financial reports and disclosures can be viewed at http://www.otcmarkets.com/stock/SNDY/filings.

Solos Endoscopy previously announced that the Depository Trust Company (DTC) imposed a Deposit Chill on new deposits. Solos management is pleased to report that it has recently been notified by The Depository Trust Company that it has determined to lift the Deposit Chill and has resumed accepting deposits of the Issue for depository and book-entry transfer services. As always Solos management advises shareholders and prospective investors to contact their financial advisors if they have questions or concerns about their individual accounts.

About Solos Endoscopy, Inc.:

Solos Endoscopy is celebrating its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.

Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact:

Solos Endoscopy, Inc.

(617) 360-9719

SOURCE Solos Endoscopy, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES